TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19539105

Group type: EXPERIMENTAL
Intervention: Aropotin (albumin-free rhEPO) 50 IU/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aropotin (albumin-free rhEPO) 100 IU/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Recormon 100 IU/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Espogen 100 IU/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Aropotin 100 IU/kg
Number of subjects: 12
Study: 16934438

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei A (100 g/day of fermented milk)
Number of subjects: 26
Study: 12174920

Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10201714

Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Midazolam hydrochloride
Number of subjects: 67

Group type: COMPARATOR
Intervention: 10% dextrose (placebo)
Number of subjects: 67
Study: 8592284

Group type: EXPERIMENTAL
Intervention: Topical butamben picrate
Number of subjects: 0
Study: 2348383

Group type: EXPERIMENTAL
Intervention: lorazepam
Number of subjects: 6

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study: 40709

Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg single dose)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg twice daily for 4 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31657646

Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Withdrawal from methylphenidate treatment
Number of subjects: 0
Study: 29357480

Group type: EXPERIMENTAL
Intervention: Low-dose recombinant human EPO (5,000 IU) over 4 weeks (n = 12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-dose recombinant human EPO (500 IU·kg body wt‐1·day‐1 for three consecutive days) (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 24
Study: 27075185

Group type: EXPERIMENTAL
Intervention: Embodied training using a randomized crossover design to divide a presented line into equal segments by walking with equally spaced steps.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control training with no involvement of task-specific whole-body movements.
Number of subjects: 0
Study: 25670222

Group type: EXPERIMENTAL
Intervention: myo-inositol
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: D-chiro inositol
Number of subjects: 137

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 137
Study: 22994682

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Combination of both drugs (NAC and ascorbic acid)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control group (saline hydration alone)
Number of subjects: 243
Study: 20605202

Group type: EXPERIMENTAL
Intervention: rosiglitazone (2 mg) and metformin (500 mg) twice daily
Number of subjects: 207

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: rosiglitazone and metformin
Number of subjects: 207
Study: 18687512

Group type: EXPERIMENTAL
Intervention: Voice advisory manikin (VAM) training
Number of subjects: 43

Group type: COMPARATOR
Intervention: Instructor facilitated (IF) training
Number of subjects: 43
Study: 16962381

Group type: EXPERIMENTAL
Intervention: Early treatment with antiretroviral therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (no early treatment)
Number of subjects: 0
Study: 12866252

Group type: EXPERIMENTAL
Intervention: Fluoxetine (n = 54)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Depression screening using SCL-90, Zung, BDI, and HADS
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Symptoms of anxiety
Number of subjects: 412
Study: 9527302

Group type: EXPERIMENTAL
Intervention: General practice intervention trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Summary measures for each practice
Number of subjects: 0
Study: 7542707

Group type: EXPERIMENTAL
Intervention: Dietary supplementation or fortification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food supplementation or fortification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supplementation trials and programs for dietary diversity and quality
Number of subjects: 0
Study: 2224785

Group type: EXPERIMENTAL
Intervention: 10-ethyl-10-deaza-aminopterin (10-EdAM)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 9
Study: 359772

Group type: EXPERIMENTAL
Intervention: Lithium carbonate treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31288233

Group type: EXPERIMENTAL
Intervention: Ustekinumab intravenous infusion followed by subcutaneous maintenance dose of 90 mg every 8 weeks
Number of subjects: 14
Study: 30957594

Group type: EXPERIMENTAL
Intervention: Mass azithromycin distribution
Number of subjects: 24
Study: 27622854

Group type: EXPERIMENTAL
Intervention: Exercise during pregnancy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sedentary control group (inactive during pregnancy)
Number of subjects: 18
Study: 25234471

Group type: COMPARATOR
Intervention: Blood Cu/Zn ratio in ASD group
Number of subjects: 52

Group type: COMPARATOR
Intervention: Blood levels of metals (Zn, Cu, Al, Pb, Hg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Uroporphyrin I, heptacarboxyporphyrin I, hexacarboxyporphyrin, pentacarboxyporphyrin I
Number of subjects: 52

Group type: COMPARATOR
Intervention: Coproporphyrin I and coproporphyrin III levels
Number of subjects: 52
Study: 24479722

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 20 mg methylprednisolone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Topical steroid eye drops (dexamethasone 1 mg/ml)
Number of subjects: 50
Study: 23040644

Group type: EXPERIMENTAL
Intervention: Harmonic Focus
Number of subjects: 128

Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 128
Study: 19398384

Group type: EXPERIMENTAL
Intervention: ACT-based acceptance intervention with values component (n = 34)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: ACT-based acceptance intervention without values component (n = 30)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (n = 35)
Number of subjects: 99
Study: 18090079

Group type: EXPERIMENTAL
Intervention: Qigong
Number of subjects: 122

Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 122
Study: 15138657

Group type: EXPERIMENTAL
Intervention: 2 days of hospital stay (Group A)
Number of subjects: 238

Group type: COMPARATOR
Intervention: More than 2 days of hospital stay (Group B)
Number of subjects: 238
Study: 12487842

Group type: EXPERIMENTAL
Intervention: Evidence-based practice (EBP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised controlled trials (RCTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guidelines and protocols
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational initiatives and organisational commitment
Number of subjects: 0
Study: 9822097

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 110

Group type: COMPARATOR
Intervention: Accelerated rt-PA
Number of subjects: 110
Study: 7662247

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (quinapril or captopril); duration: 6 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Baseline placebo period
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (quinapril or captopril)
Number of subjects: 39
Study: 29288055

Group type: EXPERIMENTAL
Intervention: Atorvastatin + Ticagrelor
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 32
Study: 27212277

Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg five times daily for one week)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 25377520

Group type: EXPERIMENTAL
Intervention: Continuing medical education (CME) on early cancer diagnosis targeting individual GPs.
Number of subjects: 836

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 836
Study: 23558303

Group type: EXPERIMENTAL
Intervention: High fluid management (8 mL/[kg · h])
Number of subjects: 102

Group type: COMPARATOR
Intervention: Low fluid management (2 mL/[kg · h])
Number of subjects: 102
Study: 20854384

Group type: EXPERIMENTAL
Intervention: Cinnamon (2g daily for 12 weeks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 19114297

Group type: EXPERIMENTAL
Intervention: Buccal midazolam (0.2mg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous diazepam (0.3mg/kg)
Number of subjects: 120
Study: 16633152

Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15317709

Group type: EXPERIMENTAL
Intervention: Foldable multifocal intraocular lenses (IOLs)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Foldable monofocal intraocular lenses (IOLs)
Number of subjects: 190
Study: 10825320

Group type: EXPERIMENTAL
Intervention: 12.5 mg dolasetron IV
Number of subjects: 200

Group type: COMPARATOR
Intervention: 25 mg dolasetron IV
Number of subjects: 200

Group type: COMPARATOR
Intervention: 4 mg ondansetron IV
Number of subjects: 200

Group type: COMPARATOR
Intervention: 8 mg ondansetron IV
Number of subjects: 200
Study: 9288632

Group type: EXPERIMENTAL
Intervention: Carcinoma in situ (10 patients)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Invasive epidermoid carcinoma (20 patients)
Number of subjects: 30
Study: 8306572

Group type: EXPERIMENTAL
Intervention: Natural IFN alpha for 12 months
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Recombinant IFN alpha 2b for 12 months
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Natural IFN alpha for 6 months
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Recombinant IFN alpha 2b for 6 months
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Natural IFN alpha for 3 months
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Recombinant IFN alpha 2b for 3 months
Number of subjects: 64
Study: 3716654

Group type: EXPERIMENTAL
Intervention: Dynamic psychotherapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Discontinued group therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group therapy (completed treatment)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standard psychoanalytic therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (discontinued group therapy)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Randomly selected group of patients (1977)
Number of subjects: 30
Study: 30646650

Group type: EXPERIMENTAL
Intervention: Nursing intervention in addition to routine treatment and respiratory function exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine treatment and respiratory function exercise
Number of subjects: 60
Study: 27698630

Group type: EXPERIMENTAL
Intervention: Dynasplint stretching (experimental group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory medication plus instructions on daily home stretching (control group)
Number of subjects: 50
Study: 23893252

Group type: EXPERIMENTAL
Intervention: e-mental health care (EMH)
Number of subjects: 1170

Group type: COMPARATOR
Intervention: occupational physician care (OP)
Number of subjects: 1170
Study: 22326506

Group type: EXPERIMENTAL
Intervention: High confederate intake
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Low confederate intake
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: No confederate intake
Number of subjects: 223
Study: 19772940

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 811

Group type: COMPARATOR
Intervention: Baseline characteristics comparison
Number of subjects: 811
Study: 18310232

Group type: EXPERIMENTAL
Intervention: Nexus coils
Number of subjects: 101

Group type: COMPARATOR
Intervention: GDC 10 coils
Number of subjects: 101

Group type: COMPARATOR
Intervention: Trufill coils
Number of subjects: 101
Study: 15793788

Group type: EXPERIMENTAL
Intervention: ACE D allele prevalence in SI group
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: DD genotype group
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 108
Study: 12425139

Group type: EXPERIMENTAL
Intervention: Fully digital hearing aid (DigiFocus compact/Oticon)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Analog digitally programmable two-channel hearing aid
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Virtual hearing aid
Number of subjects: 17
Study: 10367222

Group type: EXPERIMENTAL
Intervention: Nitroglycerin patch (10 mg/24 h) administered four hours before tests in the acute phase.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nitroglycerin patch (10 mg/24 h) administered continuously for 25 days in the chronic phase.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ECG-dipyridamole test after chronic therapy (Dip 2).
Number of subjects: 11
Study: 7738625

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens based on platinum derivatives
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Cox regression model and RECPAM analysis
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Neutrophil count
Number of subjects: 1052
Study: 1799916

Group type: EXPERIMENTAL
Intervention: Brodimoprim 200 mg once daily for 7-10 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Amoxicillin 750 mg thrice daily for 7-10 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Brodimoprim
Number of subjects: 80

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 80
Study: 7471129

Group type: EXPERIMENTAL
Intervention: 100 mg clotrimazole vaginal tablet daily for seven days (group I)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Two 100 mg clotrimazole vaginal tablets daily for three days (group II)
Number of subjects: 54
Study: 31789307

Group type: EXPERIMENTAL
Intervention: Tri-modality therapy
Number of subjects: 893
Study: 28630863

Group type: EXPERIMENTAL
Intervention: Melatonin at a dose of 2×5 mg with atorvastatin or rosuvastatin at a standardized daily dose of 20 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo with atorvastatin or rosuvastatin at a standardized daily dose of 20 mg
Number of subjects: 60
Study: 26730752

Group type: EXPERIMENTAL
Intervention: Prophylactic tracheotomy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (no tracheotomy)
Number of subjects: 39
Study: 24142869

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) 200, 400, and 600 mg daily oral dose
Number of subjects: 17

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 17
Study: 23014669

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 1795
Study: 19773681

Group type: EXPERIMENTAL
Intervention: One-stop service for antenatal syphilis screening
Number of subjects: 3850

Group type: COMPARATOR
Intervention: Conventional antenatal screening service
Number of subjects: 3850
Study: 17679493

Group type: EXPERIMENTAL
Intervention: Observation/Dialogue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observation/No Dialogue
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Observation/Dialogue
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Observation/No Dialogue
Number of subjects: 0
Study: 15283929

Group type: EXPERIMENTAL
Intervention: Soy germ isoflavones (60 mg per day, capsules)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11352236

Group type: EXPERIMENTAL
Intervention: Combination treatment with step‐down prednisolone, methotrexate, and sulfasalazine
Number of subjects: 155

Group type: COMPARATOR
Intervention: Sulfasalazine alone
Number of subjects: 155
Study: 9388790

Group type: EXPERIMENTAL
Intervention: Education plus cue enhancement using mammography chart stickers
Number of subjects: 11716

Group type: EXPERIMENTAL
Intervention: Education plus cue enhancement plus feedback and token rewards
Number of subjects: 11716

Group type: COMPARATOR
Intervention: Education-only control
Number of subjects: 11716
Study: 7956212

Group type: EXPERIMENTAL
Intervention: 35 micrograms EE OC
Number of subjects: 238

Group type: COMPARATOR
Intervention: IUD
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Norplant implants
Number of subjects: 238
Study: 3328343

Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (0.5 g/m2)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo-treated nets
Number of subjects: 389
Study: 31903866

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Moderate-intensity exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-intensity exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All intensity conditions
Number of subjects: 10
Study: 29722276

Group type: EXPERIMENTAL
Intervention: Fremanezumab 225 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fremanezumab 675 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fremanezumab 675/225 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fremanezumab 900 mg
Number of subjects: 0
Study: 28380009

Group type: EXPERIMENTAL
Intervention: Fortified biscuits
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 351
Study: 25644747

Group type: EXPERIMENTAL
Intervention: Insomnia only group
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Comorbid insomnia and obstructive sleep apnea group
Number of subjects: 211

Group type: COMPARATOR
Intervention: Groups with sleep disorders (insomnia only, obstructive sleep apnea only, comorbid)
Number of subjects: 211
Study: 23531491

Group type: EXPERIMENTAL
Intervention: Very Natural
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mostly Natural
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mostly Built
Number of subjects: 15

Group type: COMPARATOR
Intervention: Very Built
Number of subjects: 15
Study: 21062645

Group type: EXPERIMENTAL
Intervention: Moderate-intensity treatment (primary care provider counseling plus additional counseling by an auxiliary staff member)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Low-intensity control treatment (primary care provider counseling only)
Number of subjects: 261
Study: 19054832

Group type: EXPERIMENTAL
Intervention: Preoperative sub-Tenon levobupivacaine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Topical anaesthetic eye-drops only
Number of subjects: 54
Study: 16900645

Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope (GSVL)
Number of subjects: 57

Group type: COMPARATOR
Intervention: fiberoptic bronchoscope (FOB)
Number of subjects: 57
Study: 14978663

Group type: EXPERIMENTAL
Intervention: High-dose D-penicillamine (822 mg daily)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Low-dose D-penicillamine (120 mg every other day)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Active control (D-penicillamine)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Skin score
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Disability index of the Health Assessment Questionnaire (HAQ-DI)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Physician global assessment
Number of subjects: 134
Study: 12202467

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg or more)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 9620517

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4-cm PEEP
Number of subjects: 20

Group type: COMPARATOR
Intervention: 8-cm PEEP
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoflurane and Sevoflurane
Number of subjects: 20
Study: 7977218

Group type: EXPERIMENTAL
Intervention: Residential program (28-day duration)
Number of subjects: 646

Group type: COMPARATOR
Intervention: Outpatient day treatment program (28-day duration)
Number of subjects: 646
Study: 2513172

Group type: EXPERIMENTAL
Intervention: Hypercaloric nutrition (32 +/- 3.8 kcal/kg/d and 1.23 g/kg/d of protein)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hypocaloric nutrition (less than 50% of calories and same protein as Group 2)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (14 +/- 1.2 kcal/kg/d with no protein)
Number of subjects: 17
Study: 4624222

Group type: EXPERIMENTAL
Intervention: Wide excision (extended tylectomy)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 370
Study: 31218369

Group type: EXPERIMENTAL
Intervention: Two-back task (TBT) during pain
Number of subjects: 28

Group type: COMPARATOR
Intervention: REST during pain
Number of subjects: 28
Study: 28374908

Group type: EXPERIMENTAL
Intervention: p‐hCG levels measured 14 days after Day‐2 SET
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Lowest quartile of p‐hCG levels
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Three highest p‐hCG quartiles
Number of subjects: 466
Study: 26030760

Group type: EXPERIMENTAL
Intervention: Multifamily group (MFG) intervention
Number of subjects: 174
Study: 24111682

Group type: EXPERIMENTAL
Intervention: Highly foreseeable outcomes in bullying situations
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Unforeseeable outcomes in bullying situations
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Bullying situations occurring in school
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Bullying situations occurring online
Number of subjects: 163
Study: 20416959

Group type: EXPERIMENTAL
Intervention: Multi-component exercise intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continued exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continued resistance training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 19672568

Group type: EXPERIMENTAL
Intervention: EpiCor (500 mg of a dried, modified Saccharomyces cerevisiae oral fermentation product)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96